IC
RETA

Inscription Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Inscription Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,000
Closed -$302K – 229
2021
Q3 		$302K Buy
+3,000
New +$352K 0.09% 166
2021
Q2 		– Sell
-3,000
Closed -$299K – 396
2021
Q1 		$299K Buy
+3,000
New +$350K 0.1% 150

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Inscription Capital's RETA Position: Q4 2021 in Review

Inscription Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 3,000 shares — an estimated $302K sold.

Inscription Capital first reported a position in RETA in Q1 2021 and held it in 2 quarters. The position peaked at $302K in Q3 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

  • Inscription Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Inscription Capital sold 3,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $302K.
  • Inscription Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 2 quarters.
  • Inscription Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $302K in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Inscription Capital's 13F filing for Q4 2021, filed 10 Feb 2022.